See more : Fairfax Financial Holdings Limited (FRFHF) Income Statement Analysis – Financial Results
Complete financial analysis of Fulgent Genetics, Inc. (FLGT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Fulgent Genetics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Medgroup Inc. (MDGP) Income Statement Analysis – Financial Results
- Toyo Wharf & Warehouse Co., Ltd. (9351.T) Income Statement Analysis – Financial Results
- HeiQ Plc (HEIQ.L) Income Statement Analysis – Financial Results
- United Company RUSAL, International Public Joint-Stock Company (RUAL.ME) Income Statement Analysis – Financial Results
- Apoorva Leasing Finance and Investment Company Limited (APOORVA.BO) Income Statement Analysis – Financial Results
Fulgent Genetics, Inc. (FLGT)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.fulgentgenetics.com
About Fulgent Genetics, Inc.
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2001 |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 289.21M | 618.97M | 992.58M | 421.71M | 32.53M | 21.36M | 18.73M | 18.28M | 9.58M | 1.28M | 0.00 |
Cost of Revenue | 184.76M | 252.07M | 215.53M | 89.81M | 14.11M | 10.69M | 8.55M | 6.72M | 5.07M | 936.00K | 0.00 |
Gross Profit | 104.46M | 366.90M | 777.05M | 331.91M | 18.42M | 10.67M | 10.18M | 11.56M | 4.51M | 342.00K | 0.00 |
Gross Profit Ratio | 36.12% | 59.28% | 78.29% | 78.70% | 56.63% | 49.94% | 54.35% | 63.22% | 47.07% | 26.76% | 0.00% |
Research & Development | 41.44M | 28.91M | 24.22M | 11.58M | 6.54M | 5.53M | 4.22M | 3.56M | 4.43M | 521.00K | 0.00 |
General & Administrative | 89.00M | 111.07M | 50.73M | 15.22M | 6.41M | 5.54M | 5.13M | 4.61M | 2.42M | 230.00K | 0.00 |
Selling & Marketing | 41.47M | 38.92M | 24.44M | 14.95M | 5.90M | 4.65M | 4.22M | 2.47M | 2.67M | 581.00K | 0.00 |
SG&A | 130.47M | 149.99M | 75.17M | 30.17M | 12.31M | 10.19M | 9.36M | 7.08M | 5.09M | 811.00K | 0.00 |
Other Expenses | 0.00 | 6.50M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.34M |
Operating Expenses | 171.91M | 185.40M | 101.10M | 41.75M | 18.85M | 15.72M | 13.58M | 10.64M | 9.52M | 1.33M | 104.34M |
Cost & Expenses | 364.51M | 437.47M | 316.63M | 131.55M | 32.96M | 26.41M | 22.13M | 17.36M | 14.59M | 2.27M | 104.34M |
Interest Income | 21.44M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | 1.00K | 27.00K | 0.00 | 0.00 |
Interest Expense | 0.00 | 5.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.39M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 26.14M | 36.91M | 12.16M | 3.37M | 2.52M | 2.16M | 1.73M | 1.17M | 575.00K | 196.00K | 0.00 |
EBITDA | -46.55M | 221.59M | 675.95M | 290.16M | 1.68M | -2.91M | -1.75M | 2.09M | -4.44M | -794.00K | 104.34M |
EBITDA Ratio | -16.10% | 30.85% | 68.27% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -46.33% | -62.13% | 0.00% |
Operating Income | -72.70M | 178.53M | 675.95M | 290.16M | -428.00K | -5.06M | -3.40M | 919.00K | -5.01M | -990.00K | 104.34M |
Operating Income Ratio | -25.14% | 28.84% | 68.10% | 68.80% | -1.32% | -23.68% | -18.15% | 5.03% | -52.34% | -77.46% | 0.00% |
Total Other Income/Expenses | -101.39M | 5.50M | 1.35M | 1.53M | 837.00K | 434.00K | 481.00K | -5.39M | 27.00K | 0.00 | 0.00 |
Income Before Tax | -174.09M | 184.03M | 677.30M | 291.68M | 409.00K | -4.62M | -2.92M | -4.47M | -4.99M | -990.00K | 104.34M |
Income Before Tax Ratio | -60.19% | 29.73% | 68.24% | 69.17% | 1.26% | -21.65% | -15.58% | -24.45% | -52.06% | -77.46% | 0.00% |
Income Tax Expense | 1.15M | 42.10M | 174.80M | 72.53M | 43.00K | -1.07M | -768.00K | 920.00K | 3.33M | 3.29M | 0.00 |
Net Income | -167.83M | 143.40M | 507.36M | 214.31M | 366.00K | -4.49M | -2.66M | -5.39M | -8.31M | -4.28M | 104.34M |
Net Income Ratio | -58.03% | 23.17% | 51.12% | 50.82% | 1.13% | -21.02% | -14.21% | -29.48% | -86.82% | -335.13% | 0.00% |
EPS | -5.63 | 4.76 | 17.13 | 9.64 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.48 |
EPS Diluted | -5.63 | 4.63 | 16.26 | 9.09 | 0.02 | -0.25 | -0.15 | -0.30 | -0.65 | -0.34 | 3.34 |
Weighted Avg Shares Out | 29.78M | 30.10M | 29.41M | 22.69M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 29.96M |
Weighted Avg Shares Out (Dil) | 29.78M | 30.96M | 30.98M | 24.06M | 18.71M | 17.98M | 17.74M | 17.68M | 12.77M | 12.77M | 31.20M |
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Misses Revenue Estimates
Fulgent Reports First Quarter 2024 Financial Results
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
Fulgent Genetics: Buy Growth Ahead Below Liquidation Value
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
The 3 Best Digital Health Stocks for Personalized Medicine
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports